SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
July 28, 2004

ALLERGAN, INC.

(Exact name of registrant as specified in its charter)

(714) 246-4500
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Table of Contents

          (c)          Exhibits. The following exhibit is being furnished herewith:

                         99.1:          Allergan, Inc. press release dated July 28, 2004

          On July 28, 2004, Allergan, Inc. (“Allergan”) issued a press release announcing its operating results for the second quarter ended June 25, 2004. A copy of the press release is furnished as Exhibit 99.1 to this report and is hereby incorporated into this Item 12 by reference.

          In its press release Allergan included historical non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three and six month periods ended June 25, 2004, as well as the corresponding periods for 2003. Allergan believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to investors. The presentation of historical non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.

          In the press release, Allergan reported the non-GAAP financial measures “adjusted earnings” and related “adjusted diluted earnings.” Allergan uses adjusted earnings to enhance the investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities. Specifically, Allergan believes that a report of adjusted earnings provides consistency in its financial reporting and facilitates the comparison of results of core business operations between its current, past and future periods. Adjusted earnings is one of the primary indicators management uses for planning and forecasting in future periods. Allergan also uses adjusted earnings for evaluating management performance for compensation purposes.

          In the press release, Allergan also reported sales performance using the non-GAAP financial measure of constant currency sales. Constant currency sales represent current period reported sales adjusted for the translation effect of changes in average foreign exchange rates between the current period and the corresponding period in the prior year. Allergan calculates the currency effect by comparing adjusted current period reported amounts, calculated using the monthly average foreign exchange rates for the corresponding period in the prior year, to the actual current period reported amounts. Management refers to growth rates at constant currency so that sales results can be viewed without the impact of changing foreign currency exchange rates, thereby facilitating period-to-period comparisons of Allergan’s sales. Generally, when the dollar either strengthens or weakens against other currencies, the growth at constant currency rates will be higher or lower, respectively, than growth reported at actual exchange rates. Constant currency sales as defined and presented by Allergan may not be comparable to similar measures reported by other companies.

          Allergan is also holding a webcast and investor conference beginning at 8:00 a.m. Pacific Time on Wednesday, July 28, 2004 to disclose its financial results for the quarter ended June 25, 2004. The webcast can be accessed live through the Allergan website, www.allergan.com. Replays of the webcast will also be available from Wednesday, July 28, 2004 at 11:00 a.m. Pacific Time until Monday, August 2, 2004 at 7:00 p.m. Pacific Time, and can be accessed through www.allergan.com or by calling 1-866-515-1614 for domestic locations, or 1-203-369-2024 for international locations. A passcode will not be required.

          The information in this section shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit Index